Hormone Replacement Therapy (HRT) is a treatment option for managing menopausal symptoms by supplementing declining estrogen levels. However, unopposed estrogen therapy can increase the risk of endometrial hyperplasia and cancer in women with an intact uterus. To mitigate these risks, HRT regimens often include a progestogen, and Dydrogesterone is a key player in this context.

Dydrogesterone, as a synthetic progestogen, counteracts the proliferative effects of estrogen on the endometrium. It ensures that the uterine lining undergoes a secretory transformation and cyclical shedding, much like it would during a natural menstrual cycle. This action effectively protects the endometrium from hyperplasia and reduces the risk of developing endometrial cancer when used in combination with estrogen. Unlike some androgenic progestogens, dydrogesterone is noted for not negatively impacting lipid profiles or carbohydrate metabolism, which are benefits often sought in postmenopausal hormone therapy.

The administration of dydrogesterone as part of HRT is carefully managed to provide optimal benefits while minimizing potential risks. Its efficacy in endometrial protection makes it a valuable component of combined HRT regimens. For women considering HRT, understanding the role of progestogens like dydrogesterone is vital for making informed decisions about their menopausal management. Consulting with a healthcare provider is essential to determine the most suitable HRT plan, considering individual health needs and risk factors.